Compared to Estimates, ResMed (RMD) Q2 Earnings: A Look at Key Metrics

Core Insights - ResMed reported revenue of $1.28 billion for the quarter ended December 2024, reflecting a year-over-year increase of 10.3% and exceeding the Zacks Consensus Estimate of$ 1.26 billion by 1.57% [1] - The company's EPS for the quarter was $2.43, up from$ 1.88 in the same quarter last year, surpassing the consensus estimate of $2.30 by 5.65% [1] Financial Performance - ResMed's shares have returned +10.6% over the past month, outperforming the Zacks S&P 500 composite's +1.2% change, indicating strong market performance [3] - The company holds a Zacks Rank 2 (Buy), suggesting potential for continued outperformance in the near term [3] Revenue Breakdown - U.S., Canada, and Latin America - Devices generated$ 414.50 million, exceeding the average estimate of $396.91 million, with a year-over-year increase of +11.6% [4] - U.S., Canada, and Latin America - Masks and other products reported$ 334.50 million, above the average estimate of $329.71 million, marking a +12.3% year-over-year change [4] - Combined Europe, Asia, and other markets - Total revenue reached$ 376.60 million, slightly above the average estimate of $373.11 million, with a +8.1% year-over-year increase [4] - Global revenue for Total Devices was$ 669.30 million, surpassing the average estimate of $647.36 million, reflecting a +10.5% year-over-year change [4] - Global revenue for Total Sleep and Respiratory Care was$ 1.13 billion, exceeding the estimate of $1.10 billion, with a +10.6% year-over-year increase [4] - Global revenue for Total Masks and other products was$ 456.30 million, above the average estimate of $452.36 million, representing a +10.8% year-over-year change [4]